Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesElutia Inc.

Elutia Inc.

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.8359 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
21937
Market Cap
35.43M

Momentum Score

…

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.83
Low
0.88
High
52 Week Price Range
0.50
Low
1.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Elutia Inc. (NASDAQ: ELUT) is a publicly listed company for which publicly available disclosures through June 2024 provide limited detail on its operations, product portfolio and markets. Long-term growth drivers are therefore unclear from available sources but would typically depend on successful product development, regulatory approvals, commercial partnerships and access to capital; investors may find the company attractive if it achieves those milestones and demonstrates a credible path to sustainable revenue. The most important investment risks are the paucity of public information, a likely development-stage profile with regulatory and execution risk, and potential financing-related dilution, so investors should monitor SEC filings and company updates.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.84
Dividend Yield
-
Revenue TTM
12.14M
Revenue Per Share
0.28
Gross Profit TTM
7.01M
Debt / Equity
0.27
ROE
-
Net Debt
-28.77M
ROCE
-49.48%
Diluted EPS TTM
-0.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -15.86M -54.12M -41.22M -32.86M -24.78M
Net income 53.38M -53.95M -37.66M -32.90M -24.83M
Selling general administrative 15.08M 18.66M 14.10M 36.82M 32.79M
Selling and marketing expenses 5.76M 12.55M 13.09M - -
Gross profit 6.60M 10.71M 11.05M 19.22M 19.02M
Reconciled depreciation 2.79M 3.45M 3.75M 3.73M 3.73M
Ebit -18.41M -49.34M -35.42M -26.54M -22.76M
Ebitda -17.24M -45.89M -31.92M -27.58M -19.45M
Depreciation and amortization 1.17M 3.45M 3.51M - -
Operating income -18.41M -35.65M -30.53M -26.54M -23.03M
Other operating expenses 30.70M 60.03M 55.27M - -
Interest expense 0.39M 4.78M 5.80M 5.28M 5.32M
Tax provision 0.01M 0.01M 0.03M 0.03M 0.06M
Interest income 0.40M - - - -
Net interest income 0.40M -4.78M -5.80M -5.28M -5.32M
Income tax expense 0.01M 0.01M 0.03M 0.03M 0.06M
Total revenue 12.29M 24.38M 24.75M 49.19M 47.39M
Total operating expenses 25.01M 46.36M 41.58M 75.73M 70.42M
Cost of revenue 5.70M 13.67M 13.69M 29.96M 28.37M
Total other income expense net 2.55M -18.47M -10.70M -1.04M 3.58M
Net income from continuing ops -15.87M -54.13M -41.25M -32.90M -24.83M
Net income applicable to common shares - - - -32.90M -24.83M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 62.35M 36.13M 43.43M 68.84M 67.17M
Intangible assets 1.53M 8.27M 11.67M 15.07M 18.47M
Other current assets 10.27M 1.99M 2.17M 13.81M 0.04M
Total liab 34.68M 82.39M 82.03M 73.87M 53.65M
Total stockholder equity 27.67M -46.26M -38.60M -5.03M 13.52M
Other current liab 11.24M 31.94M 26.77M 17.36M 2.75M
Common stock 0.04M 0.04M - 0.02M 0.01M
Capital stock 0.04M 0.04M 0.02M 0.02M 0.01M
Retained earnings -176.21M -229.59M -175.64M -137.99M -105.09M
Other liab - - - 6.04M 17.24M
Cash 36.35M 13.24M 19.28M 16.99M 30.43M
Total current liabilities 25.14M 37.80M 43.04M 42.62M 26.00M
Net debt -28.77M 11.50M 4.40M 16.26M -
Short term debt 4.75M 1.71M - - -
Short long term debt - 1.25M 3.32M 8.99M 15.57M
Short long term debt total 7.58M 24.74M - - -
Other stockholder equity 203.84M 183.30M - - -
Property plant equipment - - - 3.07M 1.28M
Total current assets 55.82M 26.17M 31.25M 50.70M 47.43M
Net tangible assets - - - -20.10M -4.95M
Net receivables 6.58M 7.04M 3.26M 6.83M 6.00M
Long term debt - 22.60M 20.36M 24.26M 10.41M
Inventory 2.62M 3.91M 3.85M 10.05M 9.55M
Accounts payable 9.14M 4.15M 2.29M 5.48M 4.05M
Non currrent assets other - 6.50M - - 0.08M
Non current assets total 6.53M 9.96M 12.18M 18.14M 19.74M
Capital lease obligations 3.94M 0.88M 0.28M 1.64M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.47M 14.21M -0.54M -0.37M
Change to liabilities - - - 5.02M -0.80M
Total cashflows from investing activities 78.56M -0.47M 14.21M -0.54M -0.37M
Net borrowings -23.06M -2.00M -1.96M 1.62M -4.53M
Total cash from financing activities -10.64M 17.09M 9.84M 8.54M 6.71M
Change to operating activities - - - 2.02M 1.44M
Net income 53.38M -53.95M -37.66M -32.90M -24.83M
Change in cash 23.11M -6.04M 2.29M -13.44M -9.10M
Begin period cash flow 13.24M 19.28M 16.99M 30.43M 39.53M
End period cash flow 36.35M 13.24M 19.28M 16.99M 30.43M
Total cash from operating activities -44.81M -22.66M -21.76M -21.43M -15.45M
Issuance of capital stock 13.79M 12.39M 10.09M 10.41M 13.96M
Depreciation 1.17M 3.67M 3.73M 3.73M 3.73M
Other cashflows from investing activities 78.56M 0.18M 14.55M - -
Change to inventory -1.64M -0.06M -0.61M -0.50M 0.56M
Change to account receivables -0.00M 0.53M 0.80M -0.83M 1.17M
Sale purchase of stock - -1.19M -0.03M - -
Other cashflows from financing activities -1.48M 20.28M 11.83M -3.18M -2.75M
Change to netincome - - - 1.90M 3.16M
Capital expenditures 1.88M 0.65M 0.35M 0.54M 0.37M
Change in working capital -18.73M 4.09M 9.07M 5.71M 2.38M
Stock based compensation 4.40M 7.89M 2.44M 3.65M 3.54M
Other non cash items -85.04M 15.64M 0.66M -1.94M 2.77M
Free cash flow -46.69M -23.31M -22.11M -21.97M -15.81M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ELUT
Elutia Inc.		 -
-%		 0.84 - - 2.92 2.21 1.59 -3.32
ABT
Abbott Laboratories		 -0.02
0.02%		 110.51 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 1.00
0.98%		 102.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -
-%		 325.73 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.56
1.12%		 50.41 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Elutia Inc.

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

20 Firstfield Road, Gaithersburg, MD, United States, 20878

240 247 1170

https://elutia.com

25

Name Title Year Born
Mr. Kevin L. Rakin M.B.A, M.S. Executive Chairman 1961
Dr. C. Randal Mills Ph.D. Co-Founder, President & CEO and Director 1972
Mr. Matthew B. Ferguson Chief Financial Officer 1968
Ms. Erica Elchin Vice President of Global Operations NA
Dr. Michelle LeRoux Williams Ph.D. Chief Scientific Officer 1975
Ms. Courtney Guyer Vice President of Marketing NA
Dr. Sonali Fonseca Ph.D. VP & Head of Emerging Businesses NA
Mr. Jeffry D. Hamet Senior VP of Finance, Treasurer & Secretary NA
Dr. C. Randal Mills Ph.D. Co-Founder, President, CEO & Director 1972
Mr. Dwayne Montgomery Head of Cardiovascular 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…